GlassScriptPhysician profile
Roozchehr Safi
NPI 1659563641
$1,085.49
in general payments reported to CMS, 2019-2025
21 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.87 · 2021: $62.48 · 2022: $213 · 2023: $265 · 2024: $373 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $232.88 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $154.86 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $123.03 | 2022-2025 | Mavyret |
| Viiv Healthcare Company | $102.46 | 2022-2024 | Apretude, Dovato |
| Insulet Corporation | $92.15 | 2021-2023 | Omnipod |
| Scilex Pharmaceuticals INC. | $77.68 | 2023-2024 | Ztlido |
| Pfizer INC. | $37.43 | 2023-2024 | |
| Mannkind Corporation | $28.84 | 2023 | Afrezza |
| Astellas Pharma US INC | $26.12 | 2025 | Veozah |
| Kyowa Kirin, INC. | $24.32 | 2023 | |
| Optinose US, INC. | $22.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.27 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.68 | 2023 | Tradjenta |
| Otsuka America Pharmaceutical, INC. | $16.26 | 2024 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.87 | 2020 | |
| Amgen INC. | $15.71 | 2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $15.04 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $14.99 | 2023 | Heplisav-B |
| Abbott Laboratories | $14.33 | 2022 | |
| Cequr Corporation | $12.54 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roozchehr Safi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.